Access the full text.
Sign up today, get DeepDyve free for 14 days.
(SaitoMSaitoKShiraishiK. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 2018;8:310–314.29435295)
SaitoMSaitoKShiraishiK. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 2018;8:310–314.29435295SaitoMSaitoKShiraishiK. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 2018;8:310–314.29435295, SaitoMSaitoKShiraishiK. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 2018;8:310–314.29435295
(MiyoshiTUmemuraSMatsumuraY. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23:757–765.27507618)
MiyoshiTUmemuraSMatsumuraY. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23:757–765.27507618MiyoshiTUmemuraSMatsumuraY. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23:757–765.27507618, MiyoshiTUmemuraSMatsumuraY. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23:757–765.27507618
(BrambillaEBeasleyBMChirieacLRTravisWDBrambillaEBurkeAPMarxANicholsonAG. Large cell neuroendocrine carcinoma. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: IARC; 2015:69–72.)
BrambillaEBeasleyBMChirieacLRTravisWDBrambillaEBurkeAPMarxANicholsonAG. Large cell neuroendocrine carcinoma. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: IARC; 2015:69–72.BrambillaEBeasleyBMChirieacLRTravisWDBrambillaEBurkeAPMarxANicholsonAG. Large cell neuroendocrine carcinoma. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: IARC; 2015:69–72., BrambillaEBeasleyBMChirieacLRTravisWDBrambillaEBurkeAPMarxANicholsonAG. Large cell neuroendocrine carcinoma. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: IARC; 2015:69–72.
M. Fasano, C. Corte, F. Papaccio, F. Ciardiello, F. Morgillo (2015)
Pulmonary Large-Cell Neuroendocrine CarcinomaJournal of Thoracic Oncology, 10
T. Owonikoko, K. Nackaerts, T. Csőszi, G. Ostoros, C. Baik, Claudio Ullmann, E. Zagadailov, E. Sheldon-Waniga, D. Huebner, E Leonard, D. Spigel (2017)
OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)Journal of Thoracic Oncology, 12
(TanakaKIsseKFujihiraT. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–120.29290251)
TanakaKIsseKFujihiraT. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–120.29290251TanakaKIsseKFujihiraT. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–120.29290251, TanakaKIsseKFujihiraT. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–120.29290251
T. Miyoshi, S. Umemura, Y. Matsumura, S. Mimaki, S. Tada, H. Makinoshima, G. Ishii, H. Udagawa, S. Matsumoto, K. Yoh, S. Niho, H. Ohmatsu, K. Aokage, T. Hishida, J. Yoshida, K. Nagai, K. Goto, M. Tsuboi, K. Tsuchihara (2016)
Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the LungClinical Cancer Research, 23
H. Vidarsdottir, L. Tran, B. Nodin, K. Jirström, M. Planck, J. Mattsson, J. Botling, P. Micke, P. Jönsson, H. Brunnström (2018)
Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary MetastasesAmerican Journal of Clinical Pathology, 150
(HannaNBunnPAJrLangerC. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.16648503)
HannaNBunnPAJrLangerC. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.16648503HannaNBunnPAJrLangerC. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.16648503, HannaNBunnPAJrLangerC. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.16648503
N. Rekhtman, M. Pietanza, M. Hellmann, J. Naidoo, Arshi Arora, H. Won, D. Halpenny, Hangjun Wang, S. Tian, A. Litvak, P. Paik, A. Drilon, N. Socci, J. Poirier, R. Shen, M. Berger, A. Moreira, W. Travis, C. Rudin, M. Ladanyi (2016)
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsClinical Cancer Research, 22
(MorgenszternDBesseBGreillierL. Efficacy and safety of Rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958–6966.31506387)
MorgenszternDBesseBGreillierL. Efficacy and safety of Rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958–6966.31506387MorgenszternDBesseBGreillierL. Efficacy and safety of Rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958–6966.31506387, MorgenszternDBesseBGreillierL. Efficacy and safety of Rovalpituzumab Tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958–6966.31506387
D. Morgensztern, B. Besse, L. Greillier, R. Santana-Davila, N. Ready, C. Hann, B. Glisson, A. Farago, A. Dowlati, C. Rudin, S. Moulec, S. Lally, Sreeni Yalamanchili, J. Wolf, R. Govindan, D. Carbone (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyClinical Cancer Research, 25
(KomarnitskyPLeeHJShahM. 1537TiPA phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Annals of Oncology. 2017;28(suppl 5):S261–S262.)
KomarnitskyPLeeHJShahM. 1537TiPA phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Annals of Oncology. 2017;28(suppl 5):S261–S262.KomarnitskyPLeeHJShahM. 1537TiPA phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Annals of Oncology. 2017;28(suppl 5):S261–S262., KomarnitskyPLeeHJShahM. 1537TiPA phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Annals of Oncology. 2017;28(suppl 5):S261–S262.
(SaundersLRBankovichAJAndersonWC. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.)
SaundersLRBankovichAJAndersonWC. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.SaundersLRBankovichAJAndersonWC. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136., SaundersLRBankovichAJAndersonWC. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.
San-Ming Deng, Xianchun Yan, Liang Liang, Li Wang, Yuan Liu, Juanli Duan, Ziyan Yang, Tianfang Chang, B. Ruan, Qijun Zheng, Hua Han (2017)
The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice.Biochemical and biophysical research communications, 483 1
(DerksJLLeblayNLantuejoulS. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13:752–766.29454048)
DerksJLLeblayNLantuejoulS. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13:752–766.29454048DerksJLLeblayNLantuejoulS. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13:752–766.29454048, DerksJLLeblayNLantuejoulS. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13:752–766.29454048
M. Saito, Katsuharu Saito, K. Shiraishi, D. Maeda, Hiroyuki Suzuki, Y. Minamiya, K. Kono, T. Kohno, A. Goto (2017)
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.Molecular and clinical oncology, 8 2
S. Lau, Matthew Desrochers, D. Luthringer (2002)
Expression of Thyroid Transcription Factor-1, Cytokeratin 7, and Cytokeratin 20 in Bronchioloalveolar Carcinomas: an Immunohistochemical Evaluation of 67 CasesModern Pathology, 15
(den HollanderJRimpiSDohertyJR. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498–1505.20519624)
den HollanderJRimpiSDohertyJR. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498–1505.20519624den HollanderJRimpiSDohertyJR. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498–1505.20519624, den HollanderJRimpiSDohertyJR. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116:1498–1505.20519624
(MelicharBAdenisALockhartAC. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.25728526)
MelicharBAdenisALockhartAC. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.25728526MelicharBAdenisALockhartAC. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.25728526, MelicharBAdenisALockhartAC. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.25728526
(DerksJLLeblayNThunnissenE. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24:33–42.29066508)
DerksJLLeblayNThunnissenE. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24:33–42.29066508DerksJLLeblayNThunnissenE. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24:33–42.29066508, DerksJLLeblayNThunnissenE. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24:33–42.29066508
(GeorgeJWalterVPeiferM. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9:1048.29535388)
GeorgeJWalterVPeiferM. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9:1048.29535388GeorgeJWalterVPeiferM. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9:1048.29535388, GeorgeJWalterVPeiferM. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9:1048.29535388
P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W. Eberhardt, A. Nicholson, P. Groome, A. Mitchell, V. Bolejack, R. Rami-Porta, D. Ball, D. Beer, R. Beyruti, F. Detterbeck, Wilfried Eberhardt, J. Edwards, F. Galateau-Salle, D. Giroux, F. Gleeson, James Huang, C. Kennedy, Jhingook Kim, Y. Kim, L. Kingsbury, H. Kondo, M. Krasnik, K. Kubota, A. Lerut, G. Lyons, M. Marino, E. Marom, J. Meerbeeck, T. Nakano, A. Nowak, M. Peake, T. Rice, K. Rosenzweig, E. Ruffini, V. Rusch, N. Saijo, P. Schil, J. Sculier, L. Shemanski, K. Stratton, Kenji Suzuki, Y. Tachimori, C. Thomas, W. Travis, M. Tsao, A. Turrisi, J. Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, P. Baas, J. Erasmus, S. Hasegawa, K. Inai, K. Kernstine, H. Kindler, L. Krug, K. Nackaerts, H. Pass, D. Rice, C. Falkson, P. Filosso, G. Giaccone, K. Kondo, M. Lucchi, M. Okumura, E. Blackstone, A. Cavaco, A. Barrera, Abal Arca, Parente Lamelas, Arnau Obrer, Guijarro Jorge, D. Ball, G. Bascom, B. Orozco, González Castro, M. Blum, D. Chimondeguy, V. Cvijanović, S. Defranchi, B. Navarro, Escobar Campuzano, Macía Vidueira, F. Araujo, André Garcia, K. Fong, Francisco Corral, C. Gonzalez, Freixinet Gilart, García Arangüena, García Barajas, P. Girard, T. Goksel, González Budiño, González Casaurrán, Gullón Blanco, Hernández Hernández, Hernández Rodríguez, Herrero Collantes, Iglesias Heras, Izquierdo Elena, E. Jakobsen, S. Kostas, León Atance, Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles, L. Júlvez, Mariñán Gorospe, B. McCaughan, C. Kennedy, M. Íñiguez, Miravet Sorribes, Naranjo Gozalo, Álvarez Arriba, Núñez Delgado, Padilla Alarcón, Peñalver Cuesta, J. Park, H. Pass, Pavón Fernández, M. Rosenberg, E. Ruffini, V. Rusch, Sánchez Escuín, Saura Vinuesa, Serra Mitjans, T. Strand, D. Subotic, S. Swisher, R. Terra, C. Thomas, K. Tournoy, P. Schil, M. Velasquez, Y. Wu, K. Yokoi (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 11
(VidarsdottirHTranLNodinB. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol. 2018;150:533–544.30169783)
VidarsdottirHTranLNodinB. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol. 2018;150:533–544.30169783VidarsdottirHTranLNodinB. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol. 2018;150:533–544.30169783, VidarsdottirHTranLNodinB. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol. 2018;150:533–544.30169783
N. Sulai, Edward Kim, V. Ananthanarayanan (2017)
Large Cell Neuroendocrine Carcinoma
B. Melichar, A. Adenis, A. Lockhart, J. Bennouna, E. Dees, O. Kayaleh, R. Obermannova, A. DeMichele, P. Zatloukal, Bin Zhang, Claudio Ullmann, C. Schusterbauer (2015)
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.The Lancet. Oncology, 16 4
Megumi Furuta, J. Sakakibara-Konishi, H. Kikuchi, H. Yokouchi, H. Nishihara, H. Minemura, M. Harada, S. Yamazaki, K. Akie, Y. Fujita, K. Takamura, T. Kojima, T. Harada, Yoshinori Minami, N. Watanabe, S. Oizumi, Hiroyuki Suzuki, M. Nishimura, H. Dosaka-akita, H. Isobe (2019)
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).The oncologist
(BraySJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–735.27507209)
BraySJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–735.27507209BraySJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–735.27507209, BraySJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–735.27507209
Shaoying Li, V. Weiss, Xuan Wang, Parth Desai, Shimin Hu, C. Yin, G. Tang, N. Reddy, L. Medeiros, P. Lin (2015)
High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor PrognosisThe American Journal of Surgical Pathology, 40
K. Hook, S. Garza, Maruja Lira, K. Ching, N. Lee, Joan Cao, Jing Yuan, Jingjing Ye, M. Ozeck, S. Shi, Xianxian Zheng, P. Rejto, Julie Kan, J. Christensen, A. Pavlícek (2012)
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735Molecular Cancer Therapeutics, 11
J. Derks, N. Leblay, S. Lantuejoul, A. Dingemans, E. Speel, L. Fernandez-Cuesta (2018)
New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical ManagementJournal of Thoracic Oncology, 13
J. Hollander, Sara Rimpi, J. Doherty, M. Rudelius, A. Buck, Alexander Hoellein, M. Kremer, N. Graf, M. Scheerer, Mark Hall, A. Goga, N. Bubnoff, J. Duyster, C. Peschel, J. Cleveland, J. Nilsson, U. Keller (2010)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.Blood, 116 9
J. George, Vonn Walter, M. Peifer, L. Alexandrov, D. Seidel, F. Leenders, L. Maas, C. Müller, Ilona Dahmen, T. Delhomme, M. Ardin, N. Leblay, G. Byrnes, Ruping Sun, A. Reyniès, A. Mcleer-Florin, Graziella Bosco, F. Malchers, R. Menon, J. Altmüller, C. Becker, P. Nürnberg, V. Achter, Ulrich Lang, P. Schneider, Magdalena Bogus, Matthew Soloway, M. Wilkerson, Yupeng Cun, J. Mckay, D. Moro-Sibilot, C. Brambilla, S. Lantuejoul, Nicolas Lemaitre, A. Soltermann, W. Weder, V. Tischler, O. Brustugun, M. Lund-Iversen, Å. Helland, S. Solberg, S. Ansén, Gavin Wright, B. Solomon, L. Roz, U. Pastorino, I. Petersen, J. Clement, J. Sänger, J. Wolf, M. Vingron, T. Zander, S. Perner, W. Travis, S. Haas, M. Olivier, M. Foll, R. Büttner, D. Hayes, E. Brambilla, L. Fernandez-Cuesta, Roman Thomas (2018)
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumorsNature Communications, 9
S. Bray (2016)
Notch signalling in contextNature Reviews Molecular Cell Biology, 17
(LiSWeissVLWangXJ. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high p53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.26448193)
LiSWeissVLWangXJ. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high p53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.26448193LiSWeissVLWangXJ. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high p53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.26448193, LiSWeissVLWangXJ. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high p53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.26448193
J. Derks, N. Leblay, E. Thunnissen, R. Suylen, M. Bakker, H. Groen, E. Smit, R. Damhuis, E. Broek, A. Charbrier, M. Foll, J. Mckay, L. Fernandez-Cuesta, E. Speel, A. Dingemans (2017)
Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment OutcomeClinical Cancer Research, 24
(FurutaMSakakibara-KonishiJKikuchiH. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24:e1172–e1179.31068386)
FurutaMSakakibara-KonishiJKikuchiH. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24:e1172–e1179.31068386FurutaMSakakibara-KonishiJKikuchiH. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24:e1172–e1179.31068386, FurutaMSakakibara-KonishiJKikuchiH. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24:e1172–e1179.31068386
Kentaro Tanaka, K. Isse, Tomomichi Fujihira, M. Takenoyama, L. Saunders, S. Bheddah, Y. Nakanishi, I. Okamoto (2018)
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.Lung cancer, 115
(OwonikokoTNackaertsKCsosziT. Randomized phase 2 study: alisertib (MLN8237) or placebo + paclitaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol. 2017;12:S261–S262.)
OwonikokoTNackaertsKCsosziT. Randomized phase 2 study: alisertib (MLN8237) or placebo + paclitaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol. 2017;12:S261–S262.OwonikokoTNackaertsKCsosziT. Randomized phase 2 study: alisertib (MLN8237) or placebo + paclitaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol. 2017;12:S261–S262., OwonikokoTNackaertsKCsosziT. Randomized phase 2 study: alisertib (MLN8237) or placebo + paclitaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol. 2017;12:S261–S262.
(GoldstrawPChanskyKCrowleyJ. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.26762738)
GoldstrawPChanskyKCrowleyJ. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.26762738GoldstrawPChanskyKCrowleyJ. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.26762738, GoldstrawPChanskyKCrowleyJ. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.26762738
P. Komarnitsky, H. Lee, M. Shah, S. Wong, S. Gulbranson, J. Dziubinski, L. Caffrey, P. Tanwani, M. Motwani, F. Zhang (2017)
1537TiPA phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapyAnnals of Oncology, 28
R. Cardnell, Lerong Li, T. Sen, Rasha Bara, P. Tong, J. Fujimoto, A. Ireland, M. Guthrie, S. Bheddah, Upasana Banerjee, N. Kalu, Youhong Fan, S. Dylla, F. Johnson, I. Wistuba, T. Oliver, J. Heymach, B. Glisson, Jing Wang, L. Byers (2017)
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesOncotarget, 8
(CardnellRJLiLSenT. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017;8:73419–73432.29088717)
CardnellRJLiLSenT. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017;8:73419–73432.29088717CardnellRJLiLSenT. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017;8:73419–73432.29088717, CardnellRJLiLSenT. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017;8:73419–73432.29088717
(DengSMYanXCLiangL. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. Biochem Biophys Res Commun. 2017;483:488–494.28007595)
DengSMYanXCLiangL. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. Biochem Biophys Res Commun. 2017;483:488–494.28007595DengSMYanXCLiangL. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. Biochem Biophys Res Commun. 2017;483:488–494.28007595, DengSMYanXCLiangL. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. Biochem Biophys Res Commun. 2017;483:488–494.28007595
L. Saunders, A. Bankovich, Wade Anderson, M. Aujay, S. Bheddah, Kristenann Black, Radhika Desai, P. Escarpe, J. Hampl, Amy Laysang, David Liu, Javier Lopez-Molina, Milly Milton, Albert Park, Marybeth Pysz, H. Shao, Brian Slingerland, M. Torgov, Samuel Williams, O. Foord, P. Howard, J. Jassem, A. Badzio, P. Czapiewski, D. Harpole, A. Dowlati, P. Massion, W. Travis, M. Pietanza, M. Pietanza, J. Poirier, J. Poirier, C. Rudin, R. Stull, S. Dylla (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoScience Translational Medicine, 7
R. Arriagada, A. Aupérin, S. Burdett, J. Higgins, David Johnson, T. Chevalier, C. Péchoux, M. Parmar, J. Pignon, R. Souhami, R. Stephens, L. Stewart, J. Tierney, H. Tribodet, J. Meerbeeck (2010)
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataLancet, 375
N. Hanna, P. Bunn, C. Langer, L. Einhorn, T. Guthrie, T. Beck, R. Ansari, P. Ellis, M. Byrne, M. Morrison, S. Hariharan, Benjamin Wang, A. Sandler (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
(RekhtmanNPietanzaMCHellmannMD. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618–3629.26960398)
RekhtmanNPietanzaMCHellmannMD. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618–3629.26960398RekhtmanNPietanzaMCHellmannMD. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618–3629.26960398, RekhtmanNPietanzaMCHellmannMD. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618–3629.26960398
Charles Rudin, M. Pietanza, T. Bauer, N. Ready, D. Morgensztern, B. Glisson, L. Byers, M. Johnson, H. Burris, F. Robert, T. Han, S. Bheddah, Noah Theiss, S. Watson, Deepan Mathur, B. Vennapusa, H. Zayed, S. Lally, D. Strickland, R. Govindan, S. Dylla, Stanford Peng, D. Spigel (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.The Lancet. Oncology, 18 1
(NSCLC Meta-analyses Collaborative Group, ArriagadaRAuperinABurdettS. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277.20338627)
NSCLC Meta-analyses Collaborative Group, ArriagadaRAuperinABurdettS. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277.20338627NSCLC Meta-analyses Collaborative Group, ArriagadaRAuperinABurdettS. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277.20338627, NSCLC Meta-analyses Collaborative Group, ArriagadaRAuperinABurdettS. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277.20338627
(RudinCMPietanzaMCBauerTM. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.27932068)
RudinCMPietanzaMCBauerTM. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.27932068RudinCMPietanzaMCBauerTM. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.27932068, RudinCMPietanzaMCBauerTM. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.27932068
(HookKEGarzaSJLiraME. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11:710–719.22222631)
HookKEGarzaSJLiraME. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11:710–719.22222631HookKEGarzaSJLiraME. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11:710–719.22222631, HookKEGarzaSJLiraME. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11:710–719.22222631
(LauSKDesrochersMJLuthringerDJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15:538–542.12011259)
LauSKDesrochersMJLuthringerDJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15:538–542.12011259LauSKDesrochersMJLuthringerDJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15:538–542.12011259, LauSKDesrochersMJLuthringerDJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15:538–542.12011259
(FasanoMDella CorteCMPapaccioF. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–1141.26039012)
FasanoMDella CorteCMPapaccioF. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–1141.26039012FasanoMDella CorteCMPapaccioF. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–1141.26039012, FasanoMDella CorteCMPapaccioF. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–1141.26039012
The standard treatment regimen has not yet been established for advanced pulmonary large cell neuroendocrine carcinoma (LCNEC) because of its rarity. LCNEC can be subdivided into 2 mutually exclusive molecular subgroups: STK11/KEAP1 and TP53 mutated with high neuroendocrine expression and transcriptional profile of ASCL1high/DLL3high/NOTCHlow (non–small cell lung carcinoma, NSCLC-like) or RB1 and TP53 mutated with reduced neuroendocrine markers and transcriptional pattern of ASCL1low/DLL3low/NOTCHhigh (small cell lung cancer, SCLC-like). Model-based clustering shows that SCLC has subdivided into 2 major proteomic subsets defined by either TTF-1high/c-MYClow or TTF-1low/c-MYChigh, which may correspond to 2 mutually exclusive molecular subgroups: NSCLC-like or SCLC-like, respectively. We herein investigated whether TTF-1 and c-MYC could be applied to LCNEC to identify distinct subsets immunohistochemically and assessed DLL3 expression in these subsets. The protein expression profile may be useful to select patients for potential efficacy of targeted therapies including aurora kinase inhibitors for MYC alterations or anti-DLL3 antibody-drug conjugates. TTF-1 and c-MYC expression was mutually exclusive in 25 of 27 (93%) cases; TTF-1+/c-MYC- in 10, TTF-1−/c-MYC+ in 15, and TTF-1+/c-MYC+ in 2. DLL3 expression was seen in 15 of 27 cases (56%). All 12 TTF-1+ LCNEC cases were positive for DLL3. Three of 15 (20%) TTF-1−/c-MYC+ cases showed DLL3 positivity. LCNEC could be separated into 2 subsets proteomically defined by TTF-1 and c-MYC expression, which may be suitable to guide treatment selection including aurora kinase inhibitors for c-MYC+ cases. TTF-1 positivity can serve as a surrogate marker for DLL3, but caution is necessary as 20% of TTF-1− cases showed DLL3 positivity.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Oct 7, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.